Document Sample
RP110553-P1 Powered By Docstoc
					Award ID:

Project Title:
P1: Novel Therapy for Lung Cancers Using Adult Stem/Progenitor Cells

Award Mechanism:

Principal Investigator:
Malcolm K Brenner

Baylor College of Medicine

Lay Summary:

Until recently, most treatments for cancer required drugs that were poorly selective for
cancer cells. As a result, these drugs often failed to work and usually caused severe side-
effects. More recently, it has been possible to use the body’s own immune system to
fight cancer in a much more selective way. The initial benefits of this approach came
from monoclonal antibodies, which are proteins present in the liquid portion of blood that
can kill tumors with minimal side-effects. In this proposal, however, we want to exploit
the actual cells of the immune system. These cells are potentially more powerful than
antibodies. Immune cells have the ability to divide and so can increase in number after
they are given, they can actively move to the sites of tumors, and they - or their
descendants - can last the lifetime of the patient. Once immune cells reach the tumor,
they have many different ways of killing the cancer cells. In other words, a single dose of
these immune cells has the potential to completely and permanently eradicate the
cancer, with few ill-effects for the patient. Texas has exceptional scientific strengths in
this area, with investigators who have already successfully used this cellular approach to
destroy blood cancers, melanoma, neuroblastoma and cancers of the nose and throat.
These investigators have now partnered to develop and exploit each others’ technology
and create new and improved approaches to treat the disease. In 5 projects they will use
cell components called T lymphocytes, natural killer (NK) cells, tumor infiltrating
lymphocytes (TILs), dendritic cells (DC) and mesenchymal stromal cells (MSC) to attack
cancers of the lung, blood, pancreas and skin. They will work with other experts who will
run core resources and support the investigators’ ability to treat patients in a series of
clinical trials. By the end of our studies, we believe our alliance will have provided new,
effective and safe cell-therapies for otherwise incurable cancers.

Shared By: